Celcuity (NASDAQ:CELC) Trading Up 11.8% - Still a Buy?

Key Points

• Celcuity's stock price rose 11.8% to $62.25 on significant trading volume, with 780,412 shares exchanged, reflecting a 29% increase over its average session volume.
• Several analysts have issued positive ratings, with HC Wainwright raising its target price to $66 and maintaining a "buy" rating, indicating confidence in the stock's growth potential.
• The company reported a quarterly loss of ($1.04) EPS, missing estimates but is projected to improve with a consensus expectation of -2.62 EPS for the current year.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report)'s stock price traded up 11.8% on Monday . The stock traded as high as $61.59 and last traded at $62.25. 780,412 shares changed hands during trading, an increase of 29% from the average session volume of 603,669 shares. The stock had previously closed at $55.69.

Wall Street Analyst Weigh In

CELC has been the topic of a number of analyst reports. HC Wainwright boosted their price objective on shares of Celcuity from $50.00 to $66.00 and gave the company a "buy" rating in a research report on Monday, August 18th. Leerink Partners boosted their price target on shares of Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research note on Monday, July 28th. Needham & Company LLC reduced their price objective on Celcuity from $74.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Finally, Stifel Nicolaus assumed coverage on Celcuity in a report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Celcuity presently has an average rating of "Buy" and an average target price of $56.50.

Celcuity Stock Performance

The company has a debt-to-equity ratio of 2.24, a current ratio of 4.58 and a quick ratio of 4.58. The stock has a market capitalization of $2.65 billion, a PE ratio of -18.12 and a beta of 0.72. The business has a 50 day moving average price of $34.32 and a 200 day moving average price of $18.92.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.14). As a group, equities research analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Insider Activity at Celcuity

In other Celcuity news, Director David Dalvey sold 100,000 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the completion of the sale, the director directly owned 125,000 shares of the company's stock, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 15.78% of the company's stock.

Institutional Trading of Celcuity

Several hedge funds and other institutional investors have recently bought and sold shares of CELC. Ameriprise Financial Inc. increased its position in Celcuity by 45.9% during the fourth quarter. Ameriprise Financial Inc. now owns 447,171 shares of the company's stock worth $5,853,000 after buying an additional 140,642 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Celcuity by 16.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company's stock valued at $258,000 after acquiring an additional 2,756 shares in the last quarter. Bank of America Corp DE grew its stake in Celcuity by 3.9% in the 4th quarter. Bank of America Corp DE now owns 288,259 shares of the company's stock valued at $3,773,000 after buying an additional 10,907 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Celcuity by 8.9% during the 1st quarter. Rhumbline Advisers now owns 42,194 shares of the company's stock worth $427,000 after acquiring an additional 3,439 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in Celcuity in the 4th quarter valued at approximately $142,000. 63.33% of the stock is owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.